Codexis appoints Peter Strumph as interim ceo

Special committee will oversee search for a new ceo

Codexis, a developer of industrial enzymes used in the production of biofuels, bio-based chemicals and pharmaceutical intermediates, has appointed Peter Strumph as interim chief executive. Alan Shaw has resigned as president and ceo to pursue other interests. He will continue to be a special advisor to the board of directors. A special committee has been appointed to oversee the search for a new ceo and handle the transition.

Strumph was senior vice president and business head of pharmaceuticals at Codexis, where he oversaw a 49% annual increase in pharmaceutical product sales in 2011. He was also senior vice president of commercial operations. He joined Codexis in 2010.

Strumph has more than 20 years’ experience in senior manufacturing and operations management in the biopharmaceutical industry, including executive leadership positions for 10 years at CV Therapeutics.

You may also like

Ingredients

Nestlé tackles phenylketonuria with Codexis enzyme

Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)
Ingredients

Global partnership to expand pharma biocatalysis uptake

Codexis, Inc. and Porton Pharma Solutions recently announced a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. Dr Kevin Robinson caught up with Porton’s Oliver Ju and Codexis’ John Nicols to find our more
Ingredients

Codexis to exhibit at CPhI Worldwide 2017

Codexis is leading the way with powerful biocatalysts that integrate biology and chemistry
Ingredients

Codexis reports loss of US$7m in Q1

Revenue increased by 18% to $8m after significant growth in core biocatalyst R&D revenues and product sales
Manufacturing

Codexis reports 2015 fourth quarter and full year financial results

Financial outlook for 2016 is for another year of growth with revenues in the range of US$46–49m
Ingredients

Codexis files lawsuit against EnzymeWorks and its founder over alleged patent infringement

US developer of biocatalysts also alleges that Junhua (Alex) Tao misappropriated trade secrets
Manufacturing

Codexis and MSD sign multi-year extension of enzyme supply contract

Agreement covers enzyme used in manufacture of sitagliptin
Subscribe now